UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)
BIOSANTE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $0.0001 PAR VALUE PER SHARE
--------------------------------------------------------------------------------
(Title of Class of Securities)
09065 V 10 4
----------------------------------
(CUSIP Number)
DECEMBER 31, 2001
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/X/ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
Page 1 of 5
CUSIP No. 09065 V 10 4
------------
-------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Victor Morgenstern
-------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) / /
Not Applicable
-------------------------------------------------------------------------------
(3) SEC Use Only
-------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States of America
-------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 2,950,000 (see Item 4)
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With: 2,175,000 (see Item 4)
--------------------------------------------------
(7) Sole Dispositive Power
2,950,000 (see Item 4)
--------------------------------------------------
(8) Shared Dispositive Power
2,175,000 (see Item 4)
-------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
5,125,000 (see Item 4)
-------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
Not Applicable
-------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
7.9%
-------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
IN
-------------------------------------------------------------------------------
Page 2 of 5
ITEM 1.
(a) Name of Issuer
The name of the issuer is BioSante Pharmaceuticals, Inc.
---------------------------------------------------------------------
(b) Address of Issuer's Principal Executive Offices
The address of the principal executive offices of BioSante is 111
Barclay Boulevard, Suite 280, Lincolnshire, Illinois 60069.
---------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
Victor Morgenstern.
---------------------------------------------------------------------
(b) Address of Principal Business Office or, if none, Residence
The address of Mr. Morgenstern's principal place of business is c/o
Harris Associates, LP, 2 North LaSalle Street, Suite 500, Chicago,
Illinois 60602.
---------------------------------------------------------------------
(c) Citizenship
Mr. Morgenstern is a United States citizen.
---------------------------------------------------------------------
(d) Title of Class of Securities
The class of equity securities to which this Statement relates is
the common stock, $0.0001 par value per share, of BioSante
Pharmaceuticals, Inc.
---------------------------------------------------------------------
(e) CUSIP Number
The CUSIP number of the common stock is 09065 V 10 4.
---------------------------------------------------------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) / / Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o).
(b) / / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) / / Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) / / Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) / / An investment adviser in accordance with section
240.13d-1(b)(1)(ii)(E).
(f) / / An employee benefit plan or endowment fund in accordance with
section 240.13d-1(b)(1)(ii)(F).
Page 3 of 5
(g) / / A parent holding company or control person in accordance with
section 240.13d-1(b)(1)(ii)(G).
(h) / / A savings association as defined in section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813).
(i) / / A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940
(15 U.S.C. 80a-3).
(j) / / Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
Mr. Morgenstern's beneficial ownership includes: (1)
1,900,000 shares of common stock; (2) 950,000 shares of
common stock issuable upon exercise of a warrant; (3) 100,000
shares of common stock issuable upon exercise of stock
options; (4) 325,000 shares of common stock issuable upon
exercise of a warrant and 800,000 shares of common stock held
by Mr. Morgenstern's wife as trustee of the Morningstar
Trust, as to which Mr. Morgenstern disclaims beneficial
ownership; (5) 100,000 shares of common stock issuable upon
exercise of a warrant and 200,000 shares of common stock held
by Mr. Morgenstern's wife, as to which Mr. Morgenstern
disclaims control, direct or beneficial ownership; and (6)
250,000 shares of common stock issuable upon exercise of a
warrant and 500,000 shares of common stock held by Resolute
Partners. Mr. Morgenstern is a partner of Resolute Partners.
---------------------------------------------------------------------------
(b) Percent of class:
Percent of class: 7.9%. The foregoing percentage is calculated based
on the 63,208,798 shares of common stock reported to be outstanding
by BioSante on its most recently filed quarterly report on Form
10-QSB for the quarter ended September 30, 2001.
---------------------------------------------------------------------------
(c) Number of shares as to which Mr. Morgenstern has:
(i) Sole power to vote or to direct the vote
2,950,000
-------------------------------------------------------------------
(ii) Shared power to vote or to direct the vote
2,175,000
-------------------------------------------------------------------
(iii) Sole power to dispose or to direct the disposition of
2,950,000
-------------------------------------------------------------------
(iv) Shared power to dispose or to direct the disposition of
2,175,000
-------------------------------------------------------------------
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following. / /
Not Applicable.
Page 4 of 5
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not Applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable.
ITEM 10. CERTIFICATION
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
February 5, 2002
----------------------------------------
Date
/s/ VICTOR MORGENSTERN
----------------------------------------
Victor Morgenstern
Page 5 of 5